SFDA CEO Visits Guy’s Hospital in London to Explore Developments in Advanced Therapies
H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), visited Guy’s Hospital in London, United Kingdom, to review its expertise and practices in medical research and advanced therapies. Dr. Aljadhey also explored opportunities to leverage British expertise in developing the regulatory environment and supporting innovation in the healthcare sector.
During the visit, Dr. Aljadhey was briefed on the integrated model of Guy’s and St Thomas’ NHS Foundation Trust, which brings together specialized healthcare, scientific research, and medical innovation. He also reviewed the Trust’s activities in clinical research and the development of advanced therapies, particularly cell and gene therapies.
Dr. Aljadhey also reviewed manufacturing practices for advanced therapies, quality assurance requirements, and standards governing clinical trials, including first-in-human trials and their associated regulatory considerations. Discussions also explored how British experience could enhance integration across scientific research, manufacturing, and regulatory oversight.
The visit reflects the SFDA’s commitment to keeping pace with scientific and technological advancements and drawing on leading international experience to develop the regulatory environment for advanced therapies and innovative medical products. These efforts support innovation in the healthcare sector and align with the objectives of Saudi Arabia’s National Biotechnology Strategy and Saudi Vision 2030.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.